{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"551"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"30"}],"units":"Participants"}],"title":"Pre-treatment deaths"},{"categories":[{"measurements":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"529"},{"groupId":"OG001","value":"205"},{"groupId":"OG002","value":"30"}],"units":"Participants"}],"title":"On-treatment deaths"},{"categories":[{"measurements":[{"groupId":"OG000","value":"389"},{"groupId":"OG001","value":"182"},{"groupId":"OG002","value":"16"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"461"},{"groupId":"OG001","value":"186"},{"groupId":"OG002","value":"25"}],"units":"Participants"}],"title":"Post-treatment deaths"},{"categories":[{"measurements":[{"groupId":"OG000","value":"457"},{"groupId":"OG001","value":"201"},{"groupId":"OG002","value":"21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"551"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"30"}],"units":"Participants"}],"title":"All deaths"}],"denoms":[{"counts":[{"groupId":"OG000","value":"551"},{"groupId":"OG001","value":"280"},{"groupId":"OG002","value":"30"}],"units":"Participants"}],"description":"Pre-treatment deaths were collected from day of participant's informed consent to the day before first dose of study medication.\n\nOn-treatment deaths were collected from first dose of study medication to 30 days after last dose of study medication (on-treatment), up to approximately 43 months.\n\nDeaths were collected in the post treatment survival follow up from 31 days after last dose of study medication until the end of the study, up to approximately 66 months. These are not considered AEs","groups":[{"description":"Patients randomized to receive the investigational product received 7.4 GBq (+/- 10%) 177Lu-PSMA-617 intravenously every 6 weeks (+/- 1 week) for a maximum of 6 cycles. Best supportive/best standard of care (BS/BSOC) might be used","id":"OG000","title":"Main Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)"},{"description":"Patients randomized to this arm received best supportive/best standard of care (BS/BSOC) as determined by the investigator","id":"OG001","title":"Main Study: Best Supportive/Best Standard of Care (BS/BSOC) Alone"},{"description":"non-randomized cohort (AAA617+ BS/BSOC) at sites in Germany to provide a more complete assessment of the safety aspects of AAA617. Patients were treated and followed up similarly to the AAA617+BSC/BSOC (investigational arm) patients in the main study","id":"OG002","title":"Sub Study: 177Lu-PSMA-617 Plus Best Supportive/Best Standard of Care (BS/BSOC)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full Analysis Set (FAS) and the participants included in the sub-study.","reportingStatus":"POSTED","timeFrame":"Pre-treatment deaths: Up to 28 days prior to treatment. On-treatment deaths: Up to approximately 43 months. Post-treatment deaths: Up to approximately 66 months","title":"All Collected Deaths","type":"POST_HOC","unitOfMeasure":"Participants"}